PARAGANGLIOMA

This study tests a new treatment called [212Pb]VMT-α-NET for people with advanced tumors that have a specific marker (SSTR2). The treatment delivers targeted radiation to kill cancer cells while sparing healthy tissue. About 300 adults with neuroendocrine tumors or meningioma tha…

This study tests a radioactive drug called Lu-177-DOTATATE in people with rare tumors (pheochromocytoma or paraganglioma) that cannot be removed by surgery. The goal is to see if the drug can slow or stop tumor growth and to check its safety. About 130 adults will receive four do…

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The goal is to find a safe dose and see if t…

This study tests a combination of two drugs—Lutathera (a targeted radiation therapy) and olaparib (a PARP inhibitor)—in children and teens aged 3 to 18 with solid tumors that have come back or not responded to standard treatment. The goal is to find the safest dose and see if the…

This study tests whether special PET scans using targeted tracers can more accurately find and stage neuroblastoma and pheochromocytoma/paraganglioma tumors than current methods. About 30 people aged 1 to 70 will receive an injection of a radioactive tracer and then have a PET sc…

This study is testing whether a special type of PET/MRI scan, called 68Ga-DOTATATE, can better detect brain tumors or tell if a tumor has come back after treatment. The study includes 200 adults with certain brain tumors, like meningioma. The goal is to see if this scan gives doc…

This study is creating a large database to collect information about people with rare diseases like amyloidosis, sarcoidosis, and many others. Researchers will track patients' health, treatments, and outcomes over time. The goal is to better understand these conditions and improv…

This study tests a new PET scan tracer (18F-FluorThanatrace) to measure PARP-1 protein levels in people with rare adrenal tumors called pheochromocytoma or paraganglioma. About 30 adults will get one scan before their planned surgery or treatment. The results are only for researc…

This study aims to find the genes that cause pheochromocytoma and paraganglioma, rare tumors of the nervous system. Researchers will analyze DNA from up to 2,000 patients and their family members to link specific genetic changes to tumor development. The goal is to improve geneti…